Anesthetic considerations in the patient with valvular heart disease undergoing noncardiac surgery

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 12, Issue 1, 2008, Pages 33-59

  Mittnacht, Alexander J C ^a   Fanshawe, Michael ^c   Konstadt, Steven ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aortic insufficiency; Aortic stenosis; Mitral regurgitation; Mitral stenosis; Noncardiac surgery; Valvular disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ATRACURIUM; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESFLURANE; ETOMIDATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLURANE; KETAMINE; MIVACURIUM; MORPHINE; NESIRITIDE; PANCURONIUM; PROPOFOL; SEVOFLURANE; THIOPENTAL;

ANESTHESIA; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULATION; AORTA STENOSIS; AORTA VALVE REGURGITATION; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR RISK; HEMODYNAMICS; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; REVIEW; RISK ASSESSMENT; VALVULAR HEART DISEASE;

ANESTHESIA; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; CARDIOMYOPATHY, HYPERTROPHIC; HEART VALVE DISEASES; HUMANS; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE STENOSIS; POSTOPERATIVE CARE; RISK ASSESSMENT; SURGICAL PROCEDURES, OPERATIVE;

EID: 42449122217     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253208316442     Document Type: Review

References (175)

1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart disease: a population-based study. Lancet. 2006 ; 368: 1005-1011.
2. Davenport DL, Ferraris VA, Hosokawa P., Henderson WG, Khuri SF, Mentzer RM Multivariable predictors of postoperative cardiac events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg. 2007 ; 204: 1199-1210.
3. Kumar R., McKinney WP, Raj G., et al. Adverse cardiac events after surgery: assessing risk in a veteran population. J Gen Intern Med. 2001 ; 16: 507-518.
4. Sprung J., Abdelmalak B., Gottlieb A., et al. Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology. 2000 ; 93: 129-140
5. Hernandez AF, Whellan DJ, Stroud S., Sun JL, O'Connor CM, Jollis JG Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol. 2004 ; 44: 1446-1453.
6. Messika-Zeitoun D., Iung B., Philip I. Recommendations for noncardiac surgery in aortic stenosis. Ann Cardiol Angeiol. 2005 ; 54: 112-115.
7. Sista RR, Ernst KV, Ashley EA Perioperative cardiac risk: pahophysiology, assessment and management. Expert Rev Cardiovasc Ther. 2006 ; 4: 731-743.
8. Bundgaard-Nielsen M., Foss NB, Kristensen BB Use of epidural blockade in a patient with hip fracture and aortic stenosis. Eur J Anesthesiol. 2005 ; 22: 471-472.
9. Torsher LC, Shub C., Rettke SR, Brown DL Risk of patients with severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. 1998 ; 81: 448-452.
10. Delvaux B., Collinet B. Echocardiography for management of low cardiac output state after axillary block in a dehydrated patient with aortic stenosis: case report. Acta Anaesthesiol Belg. 2005 ; 56: 303-305.
11. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2007 ; 50: e159 - e241.
12. Steckelberg JM, Wilson WR Risk factors for infectious endocarditis. Infect Dis Clin North Am. 1993 ; 7: 9-19.
13. Mylonakis E., Calderwood SB Infectious endocarditis in adults. N Engl J Med. 2001 ; 345: 1318-1330.
14. Dajani AS, Taubert KA, Wilson W., et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin Infect Dis. 1997 ; 25: 1448-1458.
15. Bonow RO, Carabello BA, Chatterjee K., et al. ACC/AHA 2006 Practice guidelines for the management of patients with valvular heart disease: executive summary a report of the American College of Cardiology/American Heart a Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the society of cardiovascular anesthesiologists endorsed by the society for cardiovascular angiography and interventions and the society of thoracic surgeons. J Am Coll Cardiol. 2006 ; 48: 598-675.
16. Bach DS, Eagle RA Perioperative assessment and management of patients with valvular heart disease undergoing noncardiac surgery. Minerva Cardioangiol. 2004 ; 52: 255-261.
17. Wilson W., Taubert KA, Gewitz M., et al. Prevention of infective endocarditis. Guidelines from the American Heart Association. a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007 ; 116: 1736-1754.
18. Horlocker TT, Wedel DJ, Benzon H., et al. Regional anesthesia in the anticoagulated patient: defining the risks (The second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med. 2003 ; 28: 172-197.
19. Schouten O., Bax JJ, Dunkelgrun M., Feringa HH, Poldermans D. Pro: Beta-blockers are indicated for patients at risk for cardiac complications undergoing noncardiac surgery. Anesth Analg. 2007 ; 104: 8-10.
20. London MJ Con: Beta-blockers are indicated for all adults at increased risk undergoing noncardiac surgery. Anesth Analg. 2007 ; 104: 11-14.
21. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999 ; 100: 1043-1049.
22. Lindenauer PK, Pekow P., Wang K., Mamidi DK, Gutierrez B., Benjamin EM Perioperative beta-blocker therapy and mortality after major non-cardiac surgery. N Engl J Med. 2005 ; 353: 349-361.
23. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. Circulation. 2006 ; 113: 2662-2674.
24. Mangano DT, Layug EL, Wallace A., Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996 ; 335: 1731-1720.
25. Poldermans D., Boersma E., Bax JJ, et al. The effecy of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999 ; 341: 1789-1794.
26. Biccard BM, Sear JW, Foex P. Acute peri-operative beta blockade in intermediate risk patients. Anaesthesia. 2006 ; 61: 924-931.
27. Auerbach AD, Goldman L. Beta blockers and reduction of cardiac events in non-cardiac surgery: scientific review. JAMA. 2002 ; 287: 1435-1444.
28. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of preoperative beta blockers in non-cardiac surgery? Systematic review and meta analysis of randomized clinical trials. BMJ. 2005 ; 331: 313-321.
29. Steven RD, Burri H., Tramer MR Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesth Analg. 2003 ; 97: 623-633.
30. Venkataraman R. Vascular surgery critical care: perioperative cardiac optimization to improve survival. Crit Care Med. 2006 ; 34: S200 - S207.
31. Nakagawa H., Nanba M., Okayama J. Landiolol prevented myocardial ischemia in a patient with severe aortic stenosis undergoing total gastrectomy. Masui. 2007 ; 56: 582-585.
32. Folkeringa RJ, Van Kraaij DJ, Nieman FH, Pinto YM, Crijns HJ Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail. 2006 ; 12: 134-138.
33. Horwich TB, MacLellan WR, Fonarow GC Statin therapy s associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004 ; 43: 642-648.
34. Fukuta H., Sane DC, Brucks S., Little WC Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005 ; 112: 357-363.
35. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005 ; 96: 611-616.
36. Collard CD, Body SC, Shernan SK, Wang S., Mangano DT Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2006 ; 132: 392-400.
37. Kinlay S., Ganz P. Early statin therapy in acute coronary syndromes. Semin Vasc Med. 2003 ; 3: 419-424.
38. Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol. 2002 ; 40: 1777-1785.
39. Lindenauer PK, Pekow P., Wang K., Gutierrez B., Benjamin EM Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004 ; 291: 2092-2099.
40. Kertai MD, Boersma E., Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg. 2004 ; 28: 343-352.
41. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg. 2004 ; 39: 967-975.
42. O'Neil-Callahan K., Katsimaglis G., Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol. 2005 ; 45: 336-342.
43. Dupuis J., Tardif JC, Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE trial. Circulation. 1999 ; 99: 3227-3233.
44. Kinlay S., Schwartz GG, Olsson AG, et al. High-dose atorvastin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 ; 108: 1560-1566.
45. Poldermans D., Bax JJ, Kertai MD, et al. Statins are associated with reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003 ; 107: 1848-1851.
46. Hindler K., Shaw AD, Samuels J., et al. Improved postoperative outcomes associated with preoperative statin therapy. Anesthesiology. 2006 ; 105: 1260-1272.
47. Schouten O., Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. Am J Cardiol. 2005 ; 95: 658-660.
48. Pate GE, Tahir MN, Murphy RT, Foley JB Antiinflammatory effects of statins in patients with aortic stenosis. J Cardiovasc Pharacol Ther. 2003 ; 8: 201-206.
49. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid lowering therapy in calcific aortic stenosis. N Engl J Med. 2005 ; 352: 2389-2397.
50. Chua D., Kaib K. Statins and progression of calcified aortic stenosis. Ann Pharmacother. 2006 ; 40: 2195-2199.
51. Rossebo AB, Pedersen TR, Allen C., et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol. 2007 ; 99: 970-973.
52. Schouten O., Poldermans D., Visser L., et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing noncardiac surgery: rationale and design of the DECREASE-IV study. Am Heart J. 2004 ; 148: 1047-1052.
53. Manach YL, Godet G., Coriat P., et al. The impact of postoperative discontinuation of chronic statin therapy on cardiac outcome after major vascular surgery. Anesth Analg. 2007 ; 104: 1326-1333.
54. Heeschen C., Hamm CW, Laufs U., Snappin S., Bohm M., White HD Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002 ; 105: 1446-1452.
55. Wallace AW, Galindez D., Salahieh A., et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology. 2004 ; 101: 284-293.
56. Oliver MF, Goldman L., Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology. 1999 ; 91: 951-961.
57. Wijeysundera DN, Naik JS, Beattie WS Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med. 2003 ; 114: 742-752.
58. Yin YC, Chow LH, Tsao CM, et al. Oral clonidine reduces myocardial ischemia in patients with coronary disease undergoing noncardiac surgery. Acta Anaesthesiol Sin. 2002 ; 40: 197-203.
59. Lim P., Monin JL, Monchi M., et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B type natriuretic peptide. Eur Heart J. 2004 ; 25: 2048-2053.
60. Yusoff R., Clayton N., Keevil B., Morris J., Ray S. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol. 2006 ; 97: 1498-1501.
61. Leibowitz D., Planer D., Rott D., et al. Brain natriuretic peptide levels predict perioperative events in cardiac patients undergoing noncardiac surgery: A prospective study. Cardiology. 2007 ; 110: 266-270.
62. Gibson SC, Payne CJ, Byrne DS, et al. B-type natriuretic peptide predicts cardiac morbidity and mortality after major surgery. Br J Surg. 2007 ; 94: 903-909.
63. Cuthbertson BH, Amiri AR, Croal BL, et al. Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery. Br J Anaesth. 2007 ; 99: 170-176.
64. Feringa HH, Bax JJ, Elhendy A., et al. Association of plasma N-terminal pro-B-type natriuretic peptide with postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol. 2006 ; 98: 111-115.
65. Salzberg SP, Filsoufi F., Anyanwu A., et al. High risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg. 2005 ; 80: 502-506.
66. Shah SJ, Teerlink JR Nesiritide: a reappraisal of efficacy and safety. Expert opin Pharmacother. 2007 ; 8: 361-369.
67. Stewart BF, Siscovick D., Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997 ; 29: 630-634.
68. Lindroos M., Kupari M., Heikkila J., Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993 ; 21: 1220-1225.
69. Iivanainen AM, Lindroos M., Tilvis R., Heikkila J., Kupari M. Natural history of aortic valve stenosis of varying severity in the elderly. Am J Cardiol. 1996 ; 78: 97-101.
70. Lewin MB, Otto CM The bicuspid aortic valve: adverse outcomes from infancy to old age. Circulation. 2005 ; 111: 832-834.
71. Roberts WC, Ko JM Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005 ; 111: 920-925.
72. Januzzi JL, Isselbacher EM, Fattori R., et al. Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). J Am Coll Cardiol. 2004 ; 43: 665-669.
73. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999 ; 341: 142-147.
74. Silaruks S., Clark D., Thinkhamrop B., Sia B., Buxton B., Tonkin A. Angina pectoris and coronary artery disease in severe isolated valvular aortic stenosis. Heart Lung Circ. 2001 ; 10: 14-23.
75. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation. 2005 ; 111: 3290-3295.
76. Carabello BA Clinical practice. Aortic stenosis. N Engl J Med. 2002 ; 346: 677-682.
77. Otto CM Valvular aortic stenosis: disease severity and timing of intervention. J Am Coll Cardiol. 2006 ; 47: 2141-2151
78. Gorlin R., Gorlin SG Hydraulic formula of the area of stenotic mitral valve, other cardiac valves and central circulatory shunts. Am Heart J. 1951 ; 41: 1-29.
79. Bahler RC, Desser DR, Finkelhor RS, Brener SJ, Youssefi M. Factors leading to progression of valvular aortic stenosis. Am J Cardiol. 1999 ; 84: 1044-1048.
80. Goldman L., Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in non-cardial surgical procedures. N Engl J Med. 1977 ; 297: 845-850.
81. Rohde LE, Polanczyk CA, Goldman L., Cook EF, Lee RT, Lee TH Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery. Am J Cardiol. 2001 ; 87: 505-509.
82. Kertai MD, Bountioukos M., Boersma E., et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. Am J Med. 2004 ; 116: 8-13.
83. Zahid M., Sonel AF, Saba S., Good CB Perioperative risk of noncardiac surgery associated with aortic stenosis. Am J Cardiol. 2005 ; 96: 436-438.
84. Raymer K., Yang H. Patients with aortic stenosis: cardiac complications in non-cardiac surgery. Can J Anaesth. 1998 ; 45: 855-859.
85. Christ M., Sharkova Y., Geldner G., Maisch B. Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. Chest. 2005 ; 128: 2944-2953.
86. Lange RA, Hillis LD Dobutamine stress echocardiography in patients with low-gradient aortic stenosis. Circulation. 2006 ; 113: 1718-1720.
87. Alborino D., Hoffmann JL, Fournet PC, Bloch A. Value of exercise testing to evaluate the indication for surgery in asymptomatic patients with valvular aortic stenosis. J Heart Valve Dis. 2002 ; 11: 204-209.
88. Lancellotti P., Lebois F., Simon M., Tombeux C., Chauvel C., Pierard LA Prognostic importance of quantitative exercise doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation. 2005 ; 112 (suppl 9). 1377-382.
89. Amato MCM, Moffa PJ, Werner KE, Ramirez JAF. Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing. Heart. 2001 ; 86: 381-386.
90. Aikawa K., Otto CM Timing of aortic stenosis. Prog Cardiovasc Dis. 2001 ; 43: 477-493.
91. Levine MJ, Berman AD, Safian RD, Diver DJ, McKay RG Palliation of valvular aortic stenosis by balloon valvuloplasty as preoperative preparation for noncardiac surgery. Am J Cardiol. 1988 ; 62: 1309-1310.
92. Roth RB, Palacios IF, Block PC Percutaneous aortic balloon valvuloplasty: its role in the management of patients with aortic stenosis requiring major noncardiac surgery. J Am Coll Cardiol. 1989 ; 13: 1039-1041.
93. Hayes SN, Holmes DR, Nishimura RA, Reeder GS Palliative percutaneous aortic balloon valvuloplasty before noncardiac operations and invasive diagnostic procedures. Mayo Clin Proc. 1989 ; 64: 753-757.
94. Klein A., Lee K., Gera A., Ports TA, Michaels AD Long-term mortality, cause of death, and temporal trends in complications after percutaneous aortic balloon valvuloplasty for calcific aortic stenosis. J Interv Cardiol. 2006 ; 19: 269-275.
95. Lutter G., Ardehali R., Cremer J., Bonhoeffer P. Percutaneous valve replacement: current state and future prospects. Ann Thorac Surg. 2004 ; 78: 2199-2206.
96. McDonald SB Is neuraxial blockade contraindicated in the patient with aortic stenosis ? Reg Anesth Pain Med. 2004 ; 29: 496-502.
97. VanHelder T., Smedstad KG Combined spinal epidural anesthesia in a primigravida with valvular heart disease. Can J Anaesth. 1998 ; 45: 488-490.
98. Collard CD, Eappen S., Lynch EP, Concepcion M. Continuous spinal anesthesia with invasive hemodynamic monitoring for surgical repair of the hip in two patients with severe aortic stenosis. Anesth Analg. 1995 ; 81: 195-198.
99. Cheitlin M., Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 Guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography). J Am Soc Echocardiogr. 2003 ; 16: 1091-1110.
100. Maron BJ, McKenna WJ, Danielson GK, et al.; Task Force on Clinical Expert Consensus Documents, American College of Cardiology; European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003 ; 42: 1687-1713.
101. Poliac LC, Barron M., Maron BJ Hypertrophic cardiomyopathy. Anesthesiol. 2006 ; 104: 183-192.
102. Kovacic JC, Muller D. Hypertrophic cardiomyopathy: state-of-the-art review, with focus on the management of outflow obstruction. Intern Med J. 2003 ; 33: 521.
103. Charron P., Komajda M. Molecular genetics in hypertrophic cardiomyopathy: towards individualized management of the disease. Expert Rev Mol Diagn. 2006 ; 6: 65-78.
104. Arad M., Seidman JG, Seidman CE Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 2002 ; 11: 2499-2506.
105. Chung MW, Tsoutsman T., Semsarian C. Hypertrophic cardiomyopathy: from gene defect to clinical disease. Cell Res. 2003 ; 13: 9-20.
106. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 ; 92: 785-789.
107. Brugada R., Kelsey W., Lechin M., et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997 ; 45: 542-551.
108. Maron MS, Olivotto I., Zenovich AG, et al. Hypertrohpic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006 ; 114: 2232-2239.
109. Maron BJ, Olivotto I., Spirito P., et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000 ; 102: 858-864.
110. Maron BJ Sudden death in young athletes. N Engl J Med. 2003 ; 349: 1064-1075.
111. Elliott PM, Gimeno JR, Thaman R., et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006 ; 92: 785-791.
112. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM Clinical course of hypertrophic cardiomyopathy in a regional united states cohort. JAMA. 1999 ; 281: 650-655.
113. Sherrid MV, Chaudhry FA, Swistel DG Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann Thorac Surg. 2003 ; 75: 620.
114. Sherrid MV, Chu CK, Delia E., Mogtader A., Dwyer EM Jr. An echocardiographic study on the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993 ; 22: 816-825.
115. Sherrid MV Pathophysiology and treatment of hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2006 ; 49: 123-151.
116. Schwammenthal E., Nakatani S., He S., et al. Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility. Circulation. 1998 ; 98: 856-865.
117. Hreybe H., Zahid M., Sonel A., Good CB, Shaver J., Saba S. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006 ; 29: 65-68.
118. Haering JM, Comunale ME, Parker RA, et al. Cardiac risk of non-cardiac surgery in patients with asymmetric septal hypertrophy. Anesthesiol. 1996 ; 85: 254-259.
119. Kuroiwa M., Arai M., Ueno T., Takenaka T., Okamoto H., Hoka S. Perioperative cardiovascular complications in patients with hypertrophic cardiomyopathy. Masui. 2003 ; 52: 733-739.
120. Maron MS, Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003 ; 348: 295-303.
121. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006 ; 27: 1933-1941.
122. Spirito P., Autore C. Management of hypertrophic cardiomyopathy. BMJ. 2006 ; 332: 1251-1255.
123. Sachdev B., Hamid MS, Elliott PM The prevention of sudden death in hypertrophic cardiomyopathy. Expert Opin Pharmacother. 2002 ; 3: 499-504.
124. van der Lee C., Kofflard MJ, van Herwerden LA Sustained improvement after combined anterior mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation. 2003 ; 108: 2088-2092.
125. Ommen SR, Maron BJ, Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll cardiol. 2005 ; 46: 470-476.
126. Alam M., Dokainish H., Lakkis N. Alcohol septal ablation for hypertrophic cardiomyopathy: a systematic review of published studies. J Interv cardiol. 2006, 19: 319-327.
127. Knight CJ Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart. 2006 ; 92: 1339-1344.
128. Gietzen FH, Leuner CJ, Raute-Kreinsen U., et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999 ; 20: 1342-1354.
129. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H., Josephson ME, Kieval RS Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999 ; 99: 2927-2933.
130. Freedman RA Use of implantable pacemakers and implantable defibrillators in hypertrophic cardiomyopathy. Curr Opin Cardiol. 2001 ; 16: 58.
131. Maron BJ, Shen WK, Link MS, Epstein AE Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000 ; 342: 365.
132. Movahed MR, Ahmadi-Kashani M., Kasravi B., Saito Y. Increased prevalence of mitral stenosis in women. J Am Soc Echocardiogr. 2006 ; 19: 911-913
133. Chockalingam A., Gnanavelu G., Elangovan S., Chockalingam V. Clinical spectrum of chronic rheumatic heart disease in India. J Heart Valve Dis. 2003 ; 12: 577-581.
134. Bhatla N., Lal S., Behera G., et al. Cardiac disease in pregnancy. Int J Gynaecol Obstet. 2003 ; 82: 153-159.
135. Silversides CK, Colman JM, Sermer M., Siu SC Cardiac risk in pregnant women with rheumatic mitral stenosis. Am J Cardiol. 2003 ; 91: 1382-1385.
136. McElhinney DB, Sherwood MC, Keane JF, et al. Current management of severe congenital mitral stenosis. Outcomes of transcatheter and surgical therapy in 108 infants and children. Circulation 2005 ; 112: 707-714.
137. Nishida H., Takahara Y., Takeuchi S., Mogi K. Mitral stenosis after mitral valve repair using the duran flexible annuloplasty ring for degenerative mitral regurgitation. J Heart Valve Dis. 2005 ; 14: 563-564.
138. Horstkotte D., Niehues R., Strauer BE Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J. 1991 ; 12 (suppl B). 55-60.
139. Parissis JT, Zezas S., Sfiras N., Kastellanos S. An atypical left atrial myxoma causing intracavitary pressure gradient and typical diastolic transmitral flow of severe mitral stenosis. Int J Cardiol. 2005 ; 102: 165-167.
140. Chakko S., Bisno AL Acute rheumatic fever. In: Fuster V, Alexander RW, O' Rourke RA, eds. Hurst's The Heart. 11th ed. New York, NY: McGraw-Hill; 2004: 1635-1642.
141. Gordon SP, Douglas PS, Come PC, Manning WJ Two-dimensional and Doppler echocardiographic determinants of the natural history of mitral valve narrowing in patients with rheumatic mitral stenosis: implications for follow-up. J Am Coll Cardiol. 1992 ; 19: 968-973.
142. Diker E., Aydogdu S., Ozdemir M., et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol. 1997 ; 77: 96-98.
143. Kaymaz C., Ozdemir N., Kirma C., Sismanoglu M., Daglar B., Ozkan M. Location, size and morphological characteristics of left atrial thrombi as assessed by echocardiography in patients with rheumatic mitral valve disease. Eur J Echocardiogr. 2001 ; 2: 270-276.
144. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH Predictors of systemic embolism in patients with mitral stenosis. Ann Intern Med. 1998 ; 128: 885-889.
145. Popescu BA, Antonini-Canterin F., Temporelli PL, et al. Right ventricular functional recovery after acute myocardial infarction: relation with left ventricular function and interventricular septum motion. GISSI-3 echo substudy. Heart. 2005 ; 91: 484-488.
146. Saleh S., Liakopoulos OJ, Buckberg GD The septal motor of biventricular function. Eur J Cardiothorac Surg. 2006 ; 29 (suppl 1). S126 - S138.
147. Bonnin M., Mercier FJ, Sitbon O., et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology. 2005 ; 102: 1133-1137.
148. Rahimtoola SH, Durairaj A., Mehra A., Nuno I. Current evaluation and management of patients with mitral stenosis. Circulation. 2002 ; 106: 1183-1188.
149. Reis G., Motta MS, Barbosa MM, Esteves WA, Souza SF, Bochi EA Dobutamine stress echocardiography for non-invasive assessment and risk stratification of patients with rheumatic mitral stenosis. J Am Coll Cardiol. 2004 ; 43: 393-401.
150. Lev EI, Sagie A., Vaturi M., Sela N., Battler A., Shapira Y. Value of exercise echocardiography in rheumatic mitral stenosis with and without significant mitral regurgitation. Am J Cardiol. 2004 ; 93: 1060-1063.
151. Carabello BA Modern management of mitral stenosis. Circulation 2005 ; 112: 432-437.
152. Guerios EE, Bueno R., Nercolini R., et al. Mitral stenosis and percutaneous mitral valvuloplasty (part 1). J Invasive Cardiol. 2005 ; 17: 382-386.
153. Guerios EE, Bueno R., Nercolini R., et al. Mitral stenosis and percutaneous mitral valvuloplasty (part 2). J Invasive Cardiol. 2005 ; 17: 440-444.
154. Shaw TRD, Sutaria N., Prendergast B. Clinical and hemodynamic profiles of young, middle aged, and elderly patients with mitral stenosis undergoing mitral balloon valvotomy. Heart. 2003 ; 89: 1430-1436.
155. Ngan Kee WD, Shen J., Chiu AT, Lok I., Khaw KS Combined spinal-epidural analgesia in the management of labouring parturients with mitral stenosis. Anaesth Intensive Care. 1999 ; 27: 523-526.
156. Pan PHD, Angelo R. Anesthetic and analgesic management of mitral stenosis during pregnancy. Reg Anesth Pain Med. 2004 ; 29: 610-615.
157. Reich DL, Mittnacht A., London M., Kaplan JA Monitoring of the heart and vascular system. In: Kaplan JA, Reich DL, Lake CL, Konstadt SL, eds. Kaplan's Cardiac Anesthesia. 5 th ed. Philadelphia, PA: Saunders Elsevier. 2006: 385-436.
158. Dujardin KS, Enriquez-Sarano M., Schaff HV, Bailey KR, Sewward JB, Tajik AJ Mortality and morbidity of aortic regurgitation in clinical practice: a long-term follow up study. Circulation. 1999 ; 99: 1851-1857.
159. Groban L., Butterworth J. Perioperative management of chronic heart failure. Anesth Analg. 2006 ; 103: 557-575.
160. Comfere T., Sprung J., Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 2005 ; 100: 636-644.
161. Licker M., Schweizer A., Hohn L., Farinelli C., Morel DR Cardiovascular responses to anesthetic induction in patients chronically treated with angiotensin-converting enzyme inhibitors. Can J Anaesth. 2000 ; 47: 433-440.
162. Bertrand M., Godet G., Meersschaert K., Brun L., Salcedo E., Coriat P. Should the angiotensin II antagonists be discontinued before surgery ? Anesth Analg. 2001 ; 92: 26-30.
163. Iung B., Gohlke-Baerwolf C., Tornos P., et al. Working group on valvular heart disease: Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J. 2002 ; 23: 1253-1266.
164. Singh JP, Evans JC, Levy D., et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) Am J Cardiol. 1999 ; 83: 897-902.
165. Freed LA, Levy D., Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999 ; 341: 1-7.
166. Theal M., Sleik K., Anand S., Yi Q., Yususf S., Lonn E. Prevalence of mitral valve prolapse in ethnic groups. Can J Cardiol. 2004 ; 20: 511-515.
167. Ling LH, Enriquez-Sarano M., Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflets. N Engl J Med. 1996 ; 335: 1417-1423.
168. Grigioni F., Enriquez-Sarano M., Ling L., et al. Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol. 1999 ; 34: 2078-2085.
169. Enriquez-Sarano M., Avierinos JF, Messika-Zeitoun D., et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005 ; 352: 875-883.
170. Zoghbi WA, Enriquez-Sarano M., Foster E., et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003 ; 16: 777-802.
171. Filsoufi F., Aklog L., Byrne JG, Cohn LH, Adams DH Current results of combined coronary artery bypass grafting and mitral annuloplasty in patients with moderate ischemic mitral regurgitation. J Heart Valve Dis. 2004 ; 13: 747-753.
172. Mackey WC, Fleisher LA, Haider S., et al. Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. J Vasc Surg. 2006 ; 43: 533-538.
173. Lai HC, Lai HC, Lee WL, Wang KY, Ting CT, Liu TJ Mitral regurgitation complicates postoperative outcome of noncardiac surgery. Am Heart J. 2007 ; 153: 712-717.
174. Boersma E., Poldermans D., Bax JJ, et al. Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA. 2001 ; 285: 1865-1873.
175. Schouten O., Shaw LJ, Boersma E., et al. A meta-analysis of safety and effectiveness of perioperative beta-blocker use for the prevention of cardiac events in different types of noncardiac surgery. Coron Artery Dis. 2006 ; 17: 173-179.